![]() MB-07811 structure
|
Common Name | MB-07811 | ||
---|---|---|---|---|
CAS Number | 852948-13-1 | Molecular Weight | 514.98 | |
Density | 1.27±0.1 g/cm3(Predicted) | Boiling Point | 660.6±55.0 °C(Predicted) | |
Molecular Formula | C28H32ClO5P | Melting Point | 77-82 °C | |
MSDS | N/A | Flash Point | N/A |
Use of MB-07811MB-07811 (VK-2809) is an orally active HepDirect prodrug of MB07344, a liver-targeted thyroid hormone receptor-β agonist[1]. MB-07811 has cholesterol and triglycerides lowering activity[2]. |
Name | 4-[[4-[[(2R,4S)-4-(3-chlorophenyl)-2-oxo-1,3,2λ5-dioxaphosphinan-2-yl]methoxy]-2,6-dimethylphenyl]methyl]-2-propan-2-ylphenol |
---|
Description | MB-07811 (VK-2809) is an orally active HepDirect prodrug of MB07344, a liver-targeted thyroid hormone receptor-β agonist[1]. MB-07811 has cholesterol and triglycerides lowering activity[2]. |
---|---|
Related Catalog | |
Target |
Thyroid hormone receptor-β[2] |
In Vitro | MB-07811 is potential for liver targeting with a low affinity for thyroid hormone receptors (TRβ Ki = 14.6 ± 0.5 μM; TRα Ki = 12.5 ± 0.6 μM)[2]. |
In Vivo | MB-07811 (0.3-30 mg/kg; orally once daily for 14 days) reduces cholesterol and triglycerides in diet-induced obese mice[2]. Animal Model: 4-week-old male C57BL/6 mice (diet-induced obese (DIO) mice)[2] Dosage: 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg, 30 mg/kg Administration: Orally once daily; 14 days Result: Reduced total plasma cholesterol, and reduced plasma triglycerides (40%) at the highest doses. |
References |
Density | 1.27±0.1 g/cm3(Predicted) |
---|---|
Boiling Point | 660.6±55.0 °C(Predicted) |
Melting Point | 77-82 °C |
Molecular Formula | C28H32ClO5P |
Molecular Weight | 514.98 |
Exact Mass | 514.16800 |
PSA | 74.80000 |
LogP | 8.08420 |
Storage condition | 2-8°C |